be prudent to stop all treatment considering that injections are not cheap and come with their own complications. [4] There was no improvement in mean visual acuity although there was a significant reduction of central foveal thickness. Two patients showed some visual improvement (details are not available), seven patients showed stable vision while one showed worsening. It is possible that the visual acuity was poor to start with; hence there was no improvement in spite of anatomical improvement. Taking this into consideration-would you go ahead and recommend this as an initial treatment in all IPCV cases? We may be able to help the patients more by starting with Aflibercept before they have lost vision beyond redemption. This is especially relevant now as Ziv Aflibercept is available now (although off-label, just like Avastin) and that too at a fraction of the cost of Aflibercept. Several studies have shown Aflibercept to be superior to other anti-VEGF drugs in the treatment of IPCV. [5] Financial support and sponsorship Nil.
Reply to comment on: Aflibercept for recurrent or recalcitrant polypoidal choroidal vasculopathy in Indian eyes: Early experience
Sir, We thank you for your interest in our paper and agree with your concerns. [1, 2] All the patients were treated at our institute from the beginning. The definition of recalcitrance/resistance has been mentioned in the text. As this is a retrospective analysis of patients followed over many years, some even before the introduction of antivascular endothelial growth factors in ophthalmology, it is not possible for us to fit all the cases into defined criteria for switching agents, stopping, or continuing treatment. The reason for introducing recurrent cases to aflibercept was to ascertain the possibility of achieving an end point in treatment or at least an increase in the treatment-free interval. Failure to achieve either of the two resulted in a switch back to the original drug as long as the eye had useful vision. We agree that financial issues are important which is why our study had only ten patients, those who could afford the injection and not all cases that were resistant or recalcitrant. This particular study was not intended to test the use of either aflibercept or ziv-aflibercept as primary treatment of polypoidal choroidal vasculopathy; hence, we would not like to extrapolate our results in that direction.
Comment on: Orbital dermatofibrosarcoma protuberans with frontal and ethmoid sinus involvement: A case report and brief review of literature
Sir, I read with interest the case report by Sharma et al. on the orbital dermatofibrosarcoma protuberans (DFSP) with frontal and ethmoid sinus involvement in an Indian patient. [1] The authors nicely addressed the clinical picture, diagnostic workup, and the administered modalities of treatment. It is obvious that due to low immunity, patients infected with human immunodeficiency virus (HIV) are more vulnerable to various types of tumors in comparison to the immunocompetent individuals. Among these tumors, DFSP has been reported in HIV-positive patients. [2] To the best of my knowledge, HIV infection is an important health hazard in India. Although no recent data are yet present on the exact HIV seroprevalence in India, the available data pointed out to 0.26% seroprevalence compared with a global average of 0.2%. [3] I presume that HIV infection should be critically considered in the studied patient with the aggressive DFSP and protracted clinical course. Hence, the diagnostic algorithm of blood CD4 count and viral overload estimations for HIV infection was solicited. If that diagnostic algorithm was done and it revealed underling HIV infection, the case in question could be truly considered a novel case report as HIV-associated orbital DFSP has never been reported in the literature so far.
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